Takeda Pharmaceutical Company's stocks have experienced a series of activities recently. It started when
PNC Financial Services Group Inc. sold off a massive 255,384 shares, while both
Envestnet Portfolio Solutions Inc. and Principal Securities increased their respective holdings. Notably, TAK’s stock has been
upgraded to Buy, with a further rating enhancement to Strong Buy according to one financial advisory firm. Its FY23 operating profit, however, dipped causing the stock to sag a little. On the plus side, Takeda has secured a
licensing deal with ImmunoGen, boosting its portfolio with a promising therapeutic drug. It also reported
Q3 and
Q4 earnings showcasing its financial health. A noteworthy mention is Eohilia's FDA Approval, which brought predicted
tailwinds for the company. Among others, Takeda's stock is hailed as valuable for
value investors and lauded as a potential
Dividend King when compared with Gilead Sciences. Nonetheless, they experienced a >10% loss in a single day, prompting discussions of whether it’s
undervalued.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Thu, 30 May 2024 16:56:06 GMT -
Rating 1
- Innovation 2
- Information 8
- Rumor 2
